Drugs & Targets FDA approves Sarclisa + VRd for MM not eligible for transplant September 27, 2024Vol.50 No.36
Drugs & Targets EC approves Vyloy + chemo for advanced gastric and GEJ cancers September 27, 2024Vol.50 No.36
Drugs & Targets EU CHMP gives positive opinion to Keytruda for two types of gynecologic cancers September 27, 2024Vol.50 No.36
Drugs & Targets Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC September 27, 2024Vol.50 No.36
Drugs & Targets FDA approves Keytruda + pemetrexed + chemo in first-line mesothelioma indication September 20, 2024Vol.50 No.35
Drugs & Targets FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations September 20, 2024Vol.50 No.35
Drugs & Targets FDA approves Kisqali + aromatase inhibitor for early high-risk breast cancer September 20, 2024Vol.50 No.35
Drugs & Targets FDA grants Fast Track designation for ICT01 + Azacitidine + Venetoclax in treatment of first-line AML unfit for induction chemo September 20, 2024Vol.50 No.35
Drugs & Targets FDA issues draft guidance on conducting multiregional clinical trials in oncology September 20, 2024Vol.50 No.35
